239 related articles for article (PubMed ID: 29956369)
1. Salivary hypofunction: An update on therapeutic strategies.
Salum FG; Medella-Junior FAC; Figueiredo MAZ; Cherubini K
Gerodontology; 2018 Dec; 35(4):305-316. PubMed ID: 29956369
[TBL] [Abstract][Full Text] [Related]
2. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
Nieuw Amerongen AV; Veerman EC
Support Care Cancer; 2003 Apr; 11(4):226-31. PubMed ID: 12673460
[TBL] [Abstract][Full Text] [Related]
3. Assessing salivary gland hypofunction--Part two.
Muzyka BC
Pract Proced Aesthet Dent; 2002 Apr; 14(3):262. PubMed ID: 12004635
[No Abstract] [Full Text] [Related]
4. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations.
von Bültzingslöwen I; Sollecito TP; Fox PC; Daniels T; Jonsson R; Lockhart PB; Wray D; Brennan MT; Carrozzo M; Gandera B; Fujibayashi T; Navazesh M; Rhodus NL; Schiødt M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S57.e1-15. PubMed ID: 17379156
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the use of sialogogues in the clinical management of patients with xerostomia.
Chainani-Wu N; Gorsky M; Mayer P; Bostrom A; Epstein JB; Silverman S
Spec Care Dentist; 2006; 26(4):164-70. PubMed ID: 16927740
[TBL] [Abstract][Full Text] [Related]
6. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation.
Farag AM; Holliday C; Cimmino J; Roomian T; Papas A
Oral Dis; 2019 Nov; 25(8):1937-1944. PubMed ID: 31520497
[TBL] [Abstract][Full Text] [Related]
7. Salivary Gland Hypofunction and/or Xerostomia Induced by Nonsurgical Cancer Therapies: ISOO/MASCC/ASCO Guideline.
Mercadante V; Jensen SB; Smith DK; Bohlke K; Bauman J; Brennan MT; Coppes RP; Jessen N; Malhotra NK; Murphy B; Rosenthal DI; Vissink A; Wu J; Saunders DP; Peterson DE
J Clin Oncol; 2021 Sep; 39(25):2825-2843. PubMed ID: 34283635
[TBL] [Abstract][Full Text] [Related]
8. Salivary hypofunction and xerostomia: diagnosis and treatment.
Atkinson JC; Grisius M; Massey W
Dent Clin North Am; 2005 Apr; 49(2):309-26. PubMed ID: 15755407
[TBL] [Abstract][Full Text] [Related]
9. Management of salivary hypofunction during and after radiotherapy.
Shiboski CH; Hodgson TA; Ship JA; Schiødt M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S66.e1-19. PubMed ID: 17379158
[TBL] [Abstract][Full Text] [Related]
10. Managing the patient presenting with xerostomia: a review.
Visvanathan V; Nix P
Int J Clin Pract; 2010 Feb; 64(3):404-7. PubMed ID: 19817913
[TBL] [Abstract][Full Text] [Related]
11. Management of xerostomia and salivary gland hypofunction.
Ram S; Kumar S; Navazesh M
J Calif Dent Assoc; 2011 Sep; 39(9):656-9. PubMed ID: 22034800
[TBL] [Abstract][Full Text] [Related]
12. Management of radiotherapy-induced salivary hypofunction and consequent xerostomia in patients with oral or head and neck cancer: meta-analysis and literature review.
Lovelace TL; Fox NF; Sood AJ; Nguyen SA; Day TA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 May; 117(5):595-607. PubMed ID: 24650370
[TBL] [Abstract][Full Text] [Related]
13. Management of xerostomia related to radiotherapy for head and neck cancer.
Kahn ST; Johnstone PA
Oncology (Williston Park); 2005 Dec; 19(14):1827-32; discussion 1832-4, 1837-9. PubMed ID: 16506635
[TBL] [Abstract][Full Text] [Related]
14. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy.
Gorsky M; Epstein JB; Parry J; Epstein MS; Le ND; Silverman S
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Feb; 97(2):190-5. PubMed ID: 14970777
[TBL] [Abstract][Full Text] [Related]
16. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.
Fife RS; Chase WF; Dore RK; Wiesenhutter CW; Lockhart PB; Tindall E; Suen JY
Arch Intern Med; 2002 Jun; 162(11):1293-300. PubMed ID: 12038948
[TBL] [Abstract][Full Text] [Related]
17. Buccal drug delivery technologies for patient-centred treatment of radiation-induced xerostomia (dry mouth).
Malallah OS; Garcia CMA; Proctor GB; Forbes B; Royall PG
Int J Pharm; 2018 Apr; 541(1-2):157-166. PubMed ID: 29425763
[TBL] [Abstract][Full Text] [Related]
18. Salivary enhancement therapies.
Fox PC
Caries Res; 2004; 38(3):241-6. PubMed ID: 15153695
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study.
Leung KC; McMillan AS; Wong MC; Leung WK; Mok MY; Lau CS
Clin Rheumatol; 2008 Apr; 27(4):429-36. PubMed ID: 17899308
[TBL] [Abstract][Full Text] [Related]
20. Cevimeline (Evoxac) for dry mouth.
Med Lett Drugs Ther; 2000 Aug; 42(1084):70. PubMed ID: 10932302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
